ArticleSynthetic and systems biotechnology2025
Extending dynamic and operational range of the biosensor responding to l-carnitine by directed evolution.
Article in Synthetic and systems biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A growth-coupled progesterone-responsive biosensor for high-throughput microfluidic screening inSynthetic and systems biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
l-carnitine is a quaternary amine compound essential for eukaryotic metabolism. It is mainly involved in the oxidative decomposition of medium-and long-chain fatty acids and provides energy for the body. Therefore, it is widely used in health care and food additives. As a pivotal transcriptional activator of l-carnitine metabolism, CaiF is notably activated by crotonobetainyl-CoA, a key intermediate product in the carnitine metabolic pathway. Capitalizing on this mechanism, a sophisticated biosensor was ingeniously developed. Nevertheless, it is worth mentioning that the biosensor currently exhibits a relatively restricted detection range, which results in some specific limitations in practical application scenarios. In this paper, we constructed a biosensor based on CaiF and developed a strategy for modifying this biosensor. The structural configuration of CaiF was formulated by computer-aided design, and the DNA binding site was simulated, which was verified by alanine scanning. Functional Diversity-Oriented Volume-Conservative Substitution Strategy of the key sites of CaiF was conducted to extend the dynamic range of the biosensor. The biosensor based on CaiF
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.